Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Total Liabilities (2016 - 2025)

Wave Life Sciences' Total Liabilities history spans 11 years, with the latest figure at $112.3 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 16.73% year-over-year to $112.3 million; the TTM value through Dec 2025 reached $112.3 million, down 16.73%, while the annual FY2025 figure was $112.3 million, 16.73% down from the prior year.
  • Total Liabilities reached $112.3 million in Q4 2025 per WVE's latest filing, up from $109.0 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $294.1 million in Q1 2023 to a low of $105.2 million in Q2 2025.
  • Average Total Liabilities over 5 years is $179.9 million, with a median of $177.4 million recorded in 2021.
  • Peak YoY movement for Total Liabilities: surged 84.35% in 2023, then plummeted 48.53% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $166.6 million in 2021, then rose by 10.18% to $183.6 million in 2022, then grew by 23.88% to $227.4 million in 2023, then plummeted by 40.73% to $134.8 million in 2024, then fell by 16.73% to $112.3 million in 2025.
  • Per Business Quant, the three most recent readings for WVE's Total Liabilities are $112.3 million (Q4 2025), $109.0 million (Q3 2025), and $105.2 million (Q2 2025).